Cybin Inc. HELP

Cybin Inc. has completed a legal name change to Helus Pharma and confirmed its full slate of directors following a pivotal shareholder meeting. The rebrand comes after a sharp run in the stock, with roughly 90-day gains around 116% and 1-year gains about 116%, while 3-year and 5-year returns remain deeply negative. Analyst commentary places a fair value around $41.62 per share versus a last close near $13.00, reflecting optimism around late-stage psychedelic programs CYB003 and CYB004 targeting interventional psychiatry in clinic settings. Upside hinges on trial outcomes and on clinics and payers embracing psychedelic therapies at scale, against a backdrop of a relatively high valuation (P/B near 3.9x) compared with peers. The piece notes short-term momentum but ongoing risk in the longer term depending on clinical results and market uptake. Rebranding, leadership confirmation, and potential late-stage trial catalysts could materially alter investor sentiment and valuation.

Helus Pharma, formerly Cybin (NASDAQ: HELP), expects top-line Phase III results for HLP-003 in Q4 from the APPROACH trial, evaluating two 16-milligram doses given three weeks apart as an add-on for adults with moderate-to-severe major depressive disorder inadequately responsive to background antidepressants. Primary endpoint is six-week depression improvement (MADRS), with a 12-week readout for durability. If the broader Phase III program succeeds, Helus plans to file a New Drug Application in 2028. HLP-003 is a deuterated psilocin designed to improve brain exposure and delivery efficiency versus psilocybin. Helus is also advancing HLP-004, a deuterated DMT candidate for generalized anxiety disorder in Phase II, and an earlier-stage HLP-005 program, with lead candidate expected in 2027. CEO Michael Halstead said the company has multiple programs addressing mental health and will present data at industry forums. Top-line Phase III results for HLP-003 could meaningfully influence regulatory timing and investor sentiment.

Cybin (NasdaqGM: HELP) has climbed about 115% in the last year as fresh clinical headlines raise visibility of its psychedelic mental-health pipeline. The stock trades around a price-to-book of about 3.8x, above the pharma sector average, prompting questions whether the balance sheet and net assets justify the premium. With HLP003 (major depressive disorder) and HLP004 (anxiety) updates anticipated, investors watch how future funding needs and the pace of turning research into book-value growth could influence value. Analysts have targets, and a widely cited narrative argues Cybin may be up to 70% undervalued thanks to partnerships with Thermo Fisher for manufacturing and Osmind for clinic networks. The valuation remains sensitive to upcoming results and regulatory progress, and the next move may depend on whether the current price level is supported by the balance sheet. Upcoming clinical milestones and funding needs could moderately affect Cybin's valuation and sentiment.

Cybin Inc., doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders to vote on an auditor appointment, board size, a potential corporate name change and director elections. Shareholders were asked to appoint Zeifmans LLP as auditor and authorize the board to set its remuneration, and to approve eight directors. A special resolution sought to change the company’s name to Helus Pharma Inc. (or another board-approved name). Eight management-nominated directors were proposed: Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall, and Eric So; nominations from the floor were not accepted. Voting results were not announced at the meeting and will be disclosed later. Materials were sent to shareholders of record as of Aug. 14, 2026. Cybin is a clinical-stage biopharmaceutical company developing psychedelic-based therapeutics, including CYB003 and CYB004. Rebranding to Helus Pharma and a fixed eight-director board alongside appointing Zeifmans as auditor signals governance and branding changes with potential sentiment impact, not immediate operational shifts.

Helus Pharma presented four posters at Psych Congress 2026 evaluating HLP003, a deuterated psilocin analog, as an adjunctive treatment for major depressive disorder. The posters build on Phase 1/2a data, including 12-month efficacy results, and include a trial-in-progress overview of PARADIGM, the ongoing Phase 3 program. Posters address: effects of HLP003 on MADRS items and anhedonia; understanding the psychedelic experience; expanded safety; and the Phase 3 program’s design and aims. HLP003 has FDA Breakthrough Therapy Designation; Helus is also advancing HLP004 in Phase 2 for generalized anxiety disorder. The company notes its NSAs target serotonin pathways to promote neuroplasticity, operates in the US, Canada, the UK, and Ireland, and reiterates forward-looking statements and associated risks. Phase 3 PARADIGM progress and expanded efficacy/safety data could materially influence the company's trajectory.

Cybin expects Q4 Phase 3 data for HLP003, a deuterated psilocin analog used as adjunctive treatment for major depressive disorder under the PARADIGM program, which includes two pivotal trials (APPROACH and EMBRACE) and a one-year EXTEND extension. Phase 2 suggested roughly 13–14 point improvements at 12–16 mg after a single dose, with a second dose adding about five points, and remission rates above 70% through one year, but those results require replication in Phase 3. HLP003 has Breakthrough Therapy designation; Cybin targets NDA filing in 2028 and potential approval that year. The company also advances HLP004 for generalized anxiety disorder and reported about $166 million in cash as of June 30. Management emphasized the adjunctive approach with standard antidepressants, a rapid brain exposure profile from deuteration, a favorable safety signal, and plans to support near-term catalysts. Q4 Phase 3 data for HLP003 and potential 2028 NDA approval could materially shift Cybin's trajectory.

Helus Pharma expects a Q4 Phase III readout for HLP003, its deuterated psilocin adjunctive MDD treatment, from the APPROACH trial (223 patients) with six-week MADRS efficacy and 12-week durability and safety results. The PARADIGM program includes EMBRACE (330 planned patients) and a one-year extension. If successful, Helus targets an NDA filing in 2028 under FDA breakthrough therapy designation. HLP004, a deuterated DMT candidate for generalized anxiety disorder, is advancing after a Phase II signal-finding study, while HLP005 remains in preclinical development. Management emphasizes execution and scalable infrastructure for a potential commercial launch. The piece frames Helus within the expanding psychedelics field and notes broader market activity involving Compass Pathways, Eli Lilly/Atai, and Cybin as another player in this space. Pivotal Phase III timelines and expansion plans in psychedelics could influence sentiment around Cybin, but direct impact is limited.

Cybin advances in clinical trials while changing CEO, drawing renewed market attention to its development pipeline and leadership shift. Trial progress indicates pipeline momentum for a clinical-stage company and CEO change signals potential strategic reset affecting valuation.

Cybin stock fair value lifted as sector research supports growth assumptions. Sector research validates Cybin growth assumptions and raises stock fair value.

Helus CEO eyes Q4 Phase III depression data for HLP003 at Cybin conference. Phase III data for depression treatment could substantially shift company trajectory and investor views.

Helus Pharma reported first quarter fiscal 2027 financial results and recent business highlights. Quarterly financial results and business updates typically produce moderate effects on valuation and investor views without reshaping long-term strategy.

Cybin Inc. appointed a new CEO. The leadership change prompts questions on whether the stock remains undervalued. New CEO appointment may influence Cybin strategy and investor views on valuation.

Cybin Inc. hired Helus veteran Michael Halstead as CEO, triggering a 33.1% stock increase. New CEO appointment with relevant industry experience can materially alter strategic direction and investor sentiment.

Helus Pharma appoints Michael Halstead as Chief Executive Officer. CEO appointment may influence leadership direction and near-term strategy execution.

Cybin stock fair value moves lower as analysts rework psychedelic sector assumptions. Analyst fair value reductions may moderately shift near-term investor views on Cybin valuation.

Helus Pharma completed enrollment in its Phase 3 APPROACH Study of HLP003 ahead of schedule for adjunctive treatment of Major Depressive Disorder. Ahead-of-schedule Phase 3 enrollment accelerates HLP003 development timeline and potential market entry for major depressive disorder.

Helus Pharma completed enrollment in its Phase 3 APPROACH Study of HLP003 for adjunctive treatment of Major Depressive Disorder ahead of schedule. Ahead-of-schedule completion of Phase 3 enrollment for HLP003 in major depressive disorder accelerates potential approval timeline and revenue prospects.

Helus Pharma completed enrollment in its Phase III APPROACH study of HLP003 for adjunctive treatment of major depressive disorder ahead of schedule. Early Phase III enrollment completion accelerates potential approval timeline and strengthens competitive position in major depressive disorder treatment.

Helus Pharma completed enrollment in its Phase 3 APPROACH study of HLP003 for adjunctive treatment of major depressive disorder ahead of schedule. Early completion of Phase 3 enrollment speeds up the clinical timeline for HLP003 and supports pipeline advancement in major depressive disorder.

Cybin advances HLP003 to Phase 3 and raises US$50 million, driving a 6.2% stock increase. Phase 3 advancement plus $50 million raise marks major clinical and funding progress for core pipeline.

Cybin Inc. operating as Helus Pharma presents potential psychedelic medicine investment opportunity with HLP003 trial results pending. Pending HLP003 trial results represent major catalyst likely to shift Cybin investor sentiment and trajectory.

Helus Pharma released business highlights alongside financial results for fiscal year 2026. Year-end financial results and business updates can shift near-term investor views on operations and cash position.

Cybin Inc. stock rose 28.9% on Phase 3 progress for HLP003 combined with a $50M equity raise. Phase 3 advancement and fresh $50M capital directly strengthen Cybin's development pipeline and balance sheet.

Helus Pharma closed a US$50 million underwritten offering. $50 million capital infusion materially strengthens financial runway and supports ongoing operations.

Helus Pharma™ announces US$50 million underwritten offering. US$50 million capital raise supplies major funding to support operations and pipeline development.

Helus Pharma updated enrollment progress for its APPROACH Phase 3 trial. Phase 3 trial enrollment updates directly affect development timelines and valuation for Cybin Inc.

Correction: Helus Pharma partners with TARA Mind to advance veteran mental health initiatives. Partnership advances mental health for veterans, moderately boosting Cybin's strategic positioning in therapeutics.

Helus Pharma partners with TARA Mind to advance mental health treatments for veterans, in connection with Cybin Inc. (HELP). Partnership advances mental health initiatives in a key therapeutic area for Cybin's psychedelic development pipeline.

Robert Langer’s arrival at Cybin Inc. (HELP) prompts reassessment of confidence in the company’s clinical strategy and execution risk. Robert Langer’s expertise as a leading bioengineer strengthens Cybin’s clinical execution and investor confidence significantly.

FDA fast-tracks psychedelic drug research after Trump directive, boosting shares of psychedelic drug makers including Cybin Inc. (HELP). FDA fast-tracking psychedelic research provides significant regulatory tailwinds for Cybin's drug pipeline and market position.